General overview of the three trials with factor Xa inhibitors versus warfarin
| Aristotle apixaban | Rocket-AF rivaroxaban | Engage AF edoxaban | |
|---|---|---|---|
| Total number of patients | 18 201 | 14 264 | 21 105 |
| Primary end point | Stroke or systemic embolism | Stroke or systemic embolism | Stroke or systemic embolism |
| Drug dose (factor Xa inhibitor) | 5 mg twice daily; 2.5 mg with two or more of: age ≥80 years, body weight ≤60 kg, serum creatinine ≥1.5 mg/dL | 20 mg daily; 15 mg daily in patients with creatinine clearance 30–49 mL/min | Either 60 or 30 mg; half dose if: creatinine clearance of 30–50 mL/min, body weight ≤60 kg, concomitant use of P-glycoprotein inhibitors |
| Pretrial risk | CHADS2 score of 1 or higher (mean of 2.1) | CHADS2 score of 2 or higher (mean of 3.5) | CHADS2 score of 2 or higher (mean of 2.8) |
| Median age (years) | 70 | 73 | 72 |
| INR in therapeutic range (warfarin group) | Median of 66% | Median of 58% | Median of 68.4% |
| Arrhythmia | Atrial fibrillation or flutter | Non-valvular atrial fibrillation | Atrial fibrillation |
| Median follow-up | 1.8 years | 707 days | 2.8 years |
| Aspirin use (%) | 30.5–31.3 | 36.3–36.7 | 28.7–29.7 |
INR, international normalised ratio.